Bumrungrad Hospital Q2 2025 slides: record EBITDA margin despite revenue decline

Bumrungrad Hospital (BH) reported mixed Q2 2025 results, with revenue declining 3.6% year-over-year, yet achieving a record 41.6% EBITDA margin, signaling strong operational efficiency. Shares rose 5.36% following the announcement, which also included an increased dividend payout. While overall international patient revenue decreased, a notable 23% sequential recovery in Middle East patient revenue was observed, and strategic investments in a new cancer center and robotic surgery are underway, supported by a robust financial position.

Analysis

Bumrungrad Hospital (BH) presented a mixed Q2 2025 financial performance, characterized by top-line pressure but significant operational strength. While total revenue declined 3.6% year-over-year to 6,104 million baht, the hospital achieved a record EBITDA margin of 41.6%, a notable improvement from 40.7% in the prior-year period and a substantial recovery from 37.7% in Q1 2025. This margin expansion, despite a 6.6% YoY decrease in revenue from non-Thai patients, indicates highly effective cost control measures. A critical data point is the 23% sequential revenue growth from the Middle East market compared to Q1, suggesting a recovery in a key international segment, although this is partially offset by continued weakness in other markets like China, which saw a 21.7% YoY revenue decline. Management's confidence is underscored by an increased dividend payout to 44% of EPS and a robust balance sheet featuring a negative net debt to EBITDA ratio of -0.2x. This financial flexibility supports strategic investments, including a new comprehensive cancer center slated for 2027 and the expansion of robotic surgery capabilities, positioning BH for long-term growth in high-acuity medical tourism.

Key Decisions for Investors

• Investors should weigh the near-term revenue headwinds against the compelling evidence of operational excellence, as demonstrated by the record EBITDA margin and management's confidence signaled through an increased dividend.
• Monitor the non-Thai patient revenue mix closely in subsequent quarters, as a sustained recovery in the high-value Middle East segment is critical to offsetting weakness in other international markets and returning the company to top-line growth.
• The company's strong balance sheet and negative net debt position provide significant downside protection and substantial capacity to fund long-term growth initiatives like the new cancer center, which should be considered a key catalyst in long-term valuation models.